SGC001 / Beijing Sungen Biomedical Technology - LARVOL DELTA

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Pharmacodynamics Profile and Immunogenicity of SGC001 in Healthy Adult Subjects (ChiCTR) - P1 | N=48 | Completed | Sponsor: Beijing Anzhen Hospital Capital Medical University; Beijing Sungen Biomedical Technology Co., Ltd.

New P1 trial • Cardiovascular • Myocardial Infarction

A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (clinicaltrials.gov) - P2 | N=210 | Not yet recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd

New P2 trial • Cardiovascular • Myocardial Infarction

A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects (clinicaltrials.gov) - P1 | N=49 | Completed | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Myocardial Infarction

A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction (clinicaltrials.gov) - P1 | N=38 | Completed | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd | Active, not recruiting ➔ Completed | Trial completion date: Nov 2025 ➔ Jul 2025

Trial completion • Trial completion date • Cardiovascular • Myocardial Infarction

A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction (clinicaltrials.gov) - P1 | N=33 | Active, not recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd

New P1 trial • Cardiovascular • Myocardial Infarction

A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Beijing Sungen Biomedical Technology Co., Ltd

New P1 trial • Cardiovascular • Myocardial Infarction